Daniel Tasse - 30 May 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
30 May 2025
Transactions value $
$0
Form type
4
Filing time
03 Jun 2025, 16:33:32 UTC
Previous filing
05 Dec 2024
Next filing
24 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tasse Daniel Director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE /s/ Patrick J. Christmas as attorney-in-fact 03 Jun 2025 0001502785

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Award $0 +7.77K +68.83% $0.00 19.1K 30 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to Buy) Award $0 +39.8K $0.00 39.8K 30 May 2025 Common Stock 39.8K $8.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer.
F2 The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer.